IL165323A0 - Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments - Google Patents
Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatmentsInfo
- Publication number
- IL165323A0 IL165323A0 IL16532303A IL16532303A IL165323A0 IL 165323 A0 IL165323 A0 IL 165323A0 IL 16532303 A IL16532303 A IL 16532303A IL 16532303 A IL16532303 A IL 16532303A IL 165323 A0 IL165323 A0 IL 165323A0
- Authority
- IL
- Israel
- Prior art keywords
- dna
- checkpoint
- compounds
- damage
- ycle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/26—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/36—Esters of dithiocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38693002P | 2002-06-06 | 2002-06-06 | |
| PCT/IB2003/003164 WO2003104181A2 (en) | 2002-06-06 | 2003-06-06 | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL165323A0 true IL165323A0 (en) | 2006-01-15 |
Family
ID=29736236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16532303A IL165323A0 (en) | 2002-06-06 | 2003-06-06 | Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| IL165323A IL165323A (en) | 2002-06-06 | 2004-11-22 | Compounds that eliminate a 2 g checkpoint in the cell cycle that is attracted by DNA damage And / or aiding anti-cancer activity of DNA-damaging treatments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL165323A IL165323A (en) | 2002-06-06 | 2004-11-22 | Compounds that eliminate a 2 g checkpoint in the cell cycle that is attracted by DNA damage And / or aiding anti-cancer activity of DNA-damaging treatments |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7030111B2 (no) |
| EP (1) | EP1511713B8 (no) |
| JP (2) | JP4919598B2 (no) |
| KR (1) | KR100984951B1 (no) |
| CN (1) | CN100577631C (no) |
| AT (1) | ATE520653T1 (no) |
| AU (1) | AU2003247044B8 (no) |
| CA (1) | CA2487388C (no) |
| ES (1) | ES2369534T3 (no) |
| IL (2) | IL165323A0 (no) |
| NO (1) | NO20045556L (no) |
| WO (1) | WO2003104181A2 (no) |
| ZA (1) | ZA200409650B (no) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487388C (en) * | 2002-06-06 | 2011-05-10 | Canbas Co., Ltd. | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| JP2007501608A (ja) * | 2003-08-08 | 2007-02-01 | 株式会社 キャンバス | 抗癌治療の効力を推定するための感受性試験 |
| JPWO2007097010A1 (ja) * | 2006-02-21 | 2009-07-09 | 学校法人北里研究所 | Ｆｋｉ−２３４２物質およびその製造法 |
| EP2081565A2 (en) * | 2006-10-13 | 2009-07-29 | Reliance Life Sciences Pvt., Ltd. | Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer |
| DK2152692T3 (en) * | 2007-04-11 | 2016-09-26 | Canbas Co Ltd | EXTERNAL anti-cancer activity |
| EP3578974A1 (en) * | 2018-06-08 | 2019-12-11 | Novagray | Bleomycin for mimicking the effect of ionizing radiations on t cells |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2913483A (en) * | 1958-05-08 | 1959-11-17 | Dow Chemical Co | Lower alkylphenyl 2, 4-dichloro-benzoates |
| DE2049865A1 (en) * | 1970-10-10 | 1972-04-13 | Dynamit Nobel Ag, 5210 Troisdorf | Aromatic acid aryl esters - prepd from aromatic trichloromethyl cpds phenols and water |
| US4394389A (en) * | 1979-03-01 | 1983-07-19 | Riet Bartholomeus Van T | Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors |
| JPS56110777A (en) * | 1980-02-07 | 1981-09-02 | Chisso Corp | Ester derivative of 4-fluorobenzoic acid |
| US4612386A (en) * | 1980-09-16 | 1986-09-16 | The Dow Chemical Company | Process for making esters |
| JPS58188838A (ja) * | 1982-04-27 | 1983-11-04 | Chisso Corp | ４−（４′−フルオロベンゾイルオキシ）フエノ−ルのエステル誘導体 |
| US4934389A (en) * | 1988-12-06 | 1990-06-19 | Pettiford William L | Dental floss dispenser |
| FR2649977B1 (fr) * | 1989-07-18 | 1991-10-04 | Cird | Esters bi-aromatiques, leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| JP2696434B2 (ja) * | 1991-01-23 | 1998-01-14 | 富士写真フイルム株式会社 | 画像形成方法 |
| US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US6017958A (en) * | 1996-06-04 | 2000-01-25 | Octamer, Inc. | Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity |
| CA2216559A1 (en) * | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
| AU758241B2 (en) * | 1998-03-13 | 2003-03-20 | University Of British Columbia, The | Granulatimide derivatives for use in cancer treatment |
| KR20010042168A (ko) * | 1998-03-25 | 2001-05-25 | 바이오소스 테크놀로지스 인코포레이티드 | 혈관형성을 저해하는 벤조에이트 유도체 |
| ATE292677T1 (de) | 1999-09-22 | 2005-04-15 | Canbas Co Ltd | Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe |
| US6211164B1 (en) * | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
| DK1483290T3 (da) * | 2002-01-17 | 2008-11-03 | Takeda Pharmaceutical | Peptider og peptidmimetika, der har anti-proliferativ aktivitet og/eller forstærker nukleinsyrebeskadigende midler eller behandlinger |
| WO2003101444A1 (en) * | 2002-05-29 | 2003-12-11 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| CA2487388C (en) * | 2002-06-06 | 2011-05-10 | Canbas Co., Ltd. | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| US6881573B2 (en) * | 2003-09-12 | 2005-04-19 | Allan L. Louderback | Augmented solvent/detergent method for inactivating enveloped and non-enveloped viruses |
-
2003
- 2003-06-06 CA CA2487388A patent/CA2487388C/en not_active Expired - Fee Related
- 2003-06-06 JP JP2004511251A patent/JP4919598B2/ja not_active Expired - Fee Related
- 2003-06-06 WO PCT/IB2003/003164 patent/WO2003104181A2/en active Application Filing
- 2003-06-06 KR KR1020047019826A patent/KR100984951B1/ko not_active IP Right Cessation
- 2003-06-06 IL IL16532303A patent/IL165323A0/xx unknown
- 2003-06-06 AT AT03757173T patent/ATE520653T1/de not_active IP Right Cessation
- 2003-06-06 AU AU2003247044A patent/AU2003247044B8/en not_active Ceased
- 2003-06-06 CN CN03818476A patent/CN100577631C/zh not_active Expired - Fee Related
- 2003-06-06 US US10/457,029 patent/US7030111B2/en not_active Expired - Fee Related
- 2003-06-06 EP EP03757173A patent/EP1511713B8/en not_active Expired - Lifetime
- 2003-06-06 ES ES03757173T patent/ES2369534T3/es not_active Expired - Lifetime
-
2004
- 2004-11-22 IL IL165323A patent/IL165323A/en not_active IP Right Cessation
- 2004-11-29 ZA ZA200409650A patent/ZA200409650B/en unknown
- 2004-12-20 NO NO20045556A patent/NO20045556L/no unknown
-
2006
- 2006-01-17 US US11/334,160 patent/US7407985B2/en not_active Expired - Lifetime
-
2008
- 2008-06-02 US US12/131,564 patent/US7652042B2/en not_active Expired - Fee Related
- 2008-06-02 US US12/131,639 patent/US7629364B2/en not_active Expired - Fee Related
-
2010
- 2010-04-22 JP JP2010099281A patent/JP2010168398A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003247044A1 (en) | 2003-12-22 |
| CN100577631C (zh) | 2010-01-06 |
| EP1511713B1 (en) | 2011-08-17 |
| US20060122269A1 (en) | 2006-06-08 |
| JP2005528457A (ja) | 2005-09-22 |
| EP1511713B8 (en) | 2012-02-08 |
| US20080227827A1 (en) | 2008-09-18 |
| US7030111B2 (en) | 2006-04-18 |
| IL165323A (en) | 2015-05-31 |
| US20040198727A1 (en) | 2004-10-07 |
| NO20045556L (no) | 2005-03-04 |
| CN1671644A (zh) | 2005-09-21 |
| AU2003247044B8 (en) | 2009-04-09 |
| JP2010168398A (ja) | 2010-08-05 |
| US7629364B2 (en) | 2009-12-08 |
| US7407985B2 (en) | 2008-08-05 |
| ZA200409650B (en) | 2006-09-27 |
| ATE520653T1 (de) | 2011-09-15 |
| CA2487388C (en) | 2011-05-10 |
| AU2003247044B2 (en) | 2009-03-26 |
| WO2003104181A2 (en) | 2003-12-18 |
| WO2003104181A3 (en) | 2004-07-29 |
| ES2369534T3 (es) | 2011-12-01 |
| KR100984951B1 (ko) | 2010-10-01 |
| US20080293137A1 (en) | 2008-11-27 |
| EP1511713A2 (en) | 2005-03-09 |
| JP4919598B2 (ja) | 2012-04-18 |
| US7652042B2 (en) | 2010-01-26 |
| CA2487388A1 (en) | 2003-12-18 |
| KR20050019730A (ko) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY141119A (en) | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis | |
| MY137053A (en) | Pyrimidine derivatives and their use as cb2 modulators | |
| MX2007004551A (es) | Compuestos tiadiazol y metodos de uso. | |
| MXPA06000933A (es) | Compuestos de aminopirazol y uso como inhibidores de chk1. | |
| GB0222495D0 (en) | Compounds | |
| DE10393306D2 (de) | Mesenchymale Stammzellen des Haarfollikels und deren Verwendung | |
| WO2005030121A3 (en) | Compounds, compositions and methods | |
| NO20060518L (no) | Pyrimidiner nyttige som modulatorer av spenningsstyrte ionekanaler | |
| TW200611695A (en) | Pyrrolopyridine derivatives | |
| MX2009011025A (es) | Compuestos con actividad anticancer. | |
| NO20061194L (no) | Mitotiske kinesininbibitorer | |
| UA92503C2 (ru) | Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств | |
| ATE506953T1 (de) | 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel | |
| MXPA05013075A (es) | Inhibidores de p-38 basados en heterociclo de 5 miembros. | |
| MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
| MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
| TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. | |
| UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования | |
| ATE413392T1 (de) | Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren | |
| TW200621222A (en) | Arylsulphonylstilbene derivatives for treatment of insomnia and related conditions | |
| AU7548500A (en) | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents | |
| NO20080418L (no) | Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme | |
| ATE507218T1 (de) | Benzodiazepin-derivate als rock-kinasen hemmer | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| IL165323A0 (en) | Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |